Hypercoagulation and thrombophilia in nonalcoholic fatty liver disease: mechanisms, human evidence, therapeutic implications, and preventive implications

Semin Liver Dis. 2012 Feb;32(1):39-48. doi: 10.1055/s-0032-1306425. Epub 2012 Mar 13.

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a spectrum of disorders with a high prevalence in the industrialized world. Despite the high prevalence, the etiology and fundamental pathophysiology for the disease process is poorly understood. There is now a growing fund of knowledge suggesting that the ongoing inflammatory state associated with NAFLD leads to a low-level activation of the coagulation system. Although the data supporting this activation of the coagulation system are significant, the link with end-organ disease, mainly cardiovascular disease, is less firm and mostly epidemiological. In this review, we will explore the evidence for and against a hypercoagulable or thrombophilic state in NAFLD. We will examine possible pathophysiologic explanations and mechanisms, human epidemiologic and population-based data, and the possible therapeutic and preventative implications for treatment of thrombophilia in patients with this disease process.

Publication types

  • Review

MeSH terms

  • Anticoagulants / therapeutic use
  • Fatty Liver / complications*
  • Hepatitis / complications*
  • Humans
  • Non-alcoholic Fatty Liver Disease
  • Platelet Aggregation Inhibitors / therapeutic use
  • Thrombophilia / diagnosis
  • Thrombophilia / epidemiology
  • Thrombophilia / etiology*
  • Thrombophilia / prevention & control
  • Thrombophilia / therapy*

Substances

  • Anticoagulants
  • Platelet Aggregation Inhibitors